Chemistry:EiPLA

From HandWiki

EiPLA, also known as N-ethyl-N-isopropyllysergamide or as lysergic acid ethylisopropylamide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2][3] It is an isomer of ETH-LAD.[3]

Use and effects

EiPLA has been identified in blotter containing doses of 86 to 97 μg base equivalent per tab.[3] Blotter containing 200 μg per tab has also been described.[3] Anecdotal reports suggest that EiPLA produces psychedelic effects but is less potent than LSD.[3]

Interactions

Pharmacology

Pharmacodynamics

In drug discrimination tests in rodents, EiPLA was found to have approximately half the potency of LSD.[1][2][3]

Chemistry

Analogues

Analogues of EiPLA include MiPLA, LAMPA (MPLA), EPLA, EcPLA, and ETFELA, among others.[3][4]

History

EiPLA was first described in the scientific literature by David E. Nichols and colleagues by at least 1994.[1] It appears to have emerged as a novel designer drug by 2019.[3]

See also

References

  1. 1.0 1.1 1.2 "Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives". Pharmacology, Biochemistry, and Behavior 47 (3): 667–673. March 1994. doi:10.1016/0091-3057(94)90172-4. PMID 8208787. 
  2. 2.0 2.1 "Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)". ACS Chemical Neuroscience 9 (10): 2331–2343. October 2018. doi:10.1021/acschemneuro.8b00043. PMID 29461039. 
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 "Analytical and behavioral characterization of N-ethyl-N-isopropyllysergamide (EIPLA), an isomer of N6 -ethylnorlysergic acid N,N-diethylamide (ETH-LAD)". Drug Testing and Analysis 16 (2): 187–198. February 2024. doi:10.1002/dta.3530. PMID 37321559. 
  4. "A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies". Analyst 150 (2): 290–308. January 2025. doi:10.1039/d4an01361a. PMID 39636448.